The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•30 March 2026•

1 min read

KalVista Reports Positive Phase 3 Pediatric Data for HAE Treatment EKTERLY

Key Facts

1KalVista announced positive interim Phase 3 results from the KONFIDENT-KID trial of EKTERLY (sebetralstat).

2The study targets children aged 2-11 years with hereditary angioedema (HAE).

3The KONFIDENT-KID trial is the largest pediatric clinical trial ever conducted in HAE.

KalVista Pharmaceuticals (Nasdaq: KALV) has announced positive interim Phase 3 results from its KONFIDENT-KID trial evaluating EKTERLY (sebetralstat). The study focuses on children aged 2 to 11 years suffering from hereditary angioedema (HAE), a rare genetic condition. Notably, the KONFIDENT-KID trial represents the largest pediatric clinical study ever conducted within the HAE therapeutic area. The company aims to expand the indication of its lead candidate to younger populations using a proprietary oral disintegrating tablet formulation. This milestone significantly de-risks the regulatory path toward approval and broadens the drug's potential market reach. Investors view these results as a critical step in strengthening KalVista's position in the rare disease pharmaceutical sector.

Create Free Account